Caribou Biosciences (CRBU) Price & Analysis

Compare

851 Followers

CRBU Stock Chart & Stats

$1.87

-$0.16(-8.56%)

At close: Jan 08 4:00 PM EST

$1.87

-$0.16(-8.56%)

Day’s Range― - ―

52-Week Range$0.66 - $3.54

Previous CloseN/A

Volume598.80K

Average Volume (3M)1.20M

Market Cap

$202.08M

Enterprise Value-$40.88M

Total Cash (Recent Filing)$147.26M

Total Debt (Recent Filing)$25.46M

Price to Earnings (P/E)―

Beta2.44

Next Earnings

Mar 16, 2026

EPS Estimate

-0.31

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.30

Shares Outstanding93,123,240

10 Day Avg. Volume1,354,975

30 Day Avg. Volume1,199,069

Financial Highlights & Ratios

PEG Ratio-0.05

Price to Book (P/B)0.57

Price to Sales (P/S)14.37

P/FCF Ratio-1.00

Enterprise Value/Market Cap-0.20

Enterprise Value/Revenue-4.40

Enterprise Value/Gross Profit1.93

Enterprise Value/Ebitda0.29

Forecast

1Y Price Target

$7.00

Price Target Upside274.33% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Cash ReservesCaribou's cash reserves at the end of the quarter are expected to support operations into the second half of 2027.

Competitive PositioningThe efficacy results for CB-010 in the ANTLER trial are comparable to those of FDA-approved CAR-T therapies, suggesting strong competitive positioning.

Financial PerformanceCaribou's financial results showed a net loss per share that was better than previous estimates, indicating improved financial performance.

Bears Say

Caribou Biosciences News

Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year

Reports Q3 revenue $2.2M vs. $2.0M last year. Cash, cash equivalents, and marketable securities were $159.2M as of...

7d ago

CRBU

FDA appoints Richard Pazdur as Director of CDER

The U.S. Department of Health and Human Services and the U.S. Food and Drug Administration announced that Richard...

8d ago

AZN

BMY

Caribou Biosciences price target raised to $9 from $3 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Caribou Biosciences (CRBU) to $9 from $3 and keeps a...

15d ago

CRBU

3 Penny Stocks to Watch Now, 11/4/25

Generation Essentials Group, Phio Pharmaceuticals, and Caribou Biosciences are the 3 Penny Stocks to watch on November 4, 2025, based...

15d ago

HKD

TGE

Caribou Biosciences price target raised to $8 from $5 at Citi

Citi raised the firm’s price target on Caribou Biosciences (CRBU) to $8 from $5 and keeps a Buy...

16d ago

CRBU

Caribou Biosciences announces results from CaMMouflage Phase 1 trial

Caribou Biosciences (CRBU) announced its first clinical data from dose escalation in the ongoing CaMMouflage phase 1 trial...

17d ago

CRBU

Caribou Biosciences announces results from ANTLER phase 1 trial of vispa-cel

Caribou Biosciences (CRBU) announced positive results from its ongoing ANTLER phase 1 clinical trial evaluating vispacabtagene regedleucel, vispa-cel,...

17d ago

CRBU

Video: This stock is dragging down the in vivo gene editing therapy space

The Fly has brought its to-the-moment stock market reporting to YouTube! Listen and subscribe. Published first on TheFly...

23d ago

MGX

BEAM

Intellia Therapeutics price target lowered to $30 from $36 at BofA

BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $36 and keeps a Buy...

23d ago

BEAM

CRBU

Caribou Biosciences: Promising Financials and Clinical Success Drive Buy Rating

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Caribou Biosciences, with...

3d ago

CRBU

Caribou Biosciences Reports Increased Losses Amid R&D Focus

Caribou Biosciences, Inc. ( ($CRBU) ) has released its Q3 earnings. Here is a breakdown of the information...

7d ago

CRBU

Is CRBU a Buy, Before Earnings?

Caribou Biosciences, Inc. (CRBU) is scheduled to report 3rd quarter earnings on 11/11/2025. Regarding Q3 estimates, Wall Street...

11d ago

CRBU

Caribou Biosciences Reports Positive ANTLER Phase 1 Results

Caribou Biosciences ( ($CRBU) ) has provided an update. On November 3, 2025, Caribou Biosciences announced positive results...

17d ago

CRBU

Caribou Biosciences’ CRISPR-Edited CAR-T Therapy: A Promising Step in Multiple Myeloma Treatment

Caribou Biosciences, Inc. (($CRBU)) announced an update on their ongoing clinical study. Study Overview: Caribou Biosciences, Inc. is...

23d ago

CRBU

CRBU FAQ

What was Caribou Biosciences’s price range in the past 12 months?

Caribou Biosciences lowest stock price was $0.66 and its highest was $3.54 in the past 12 months.

What is Caribou Biosciences’s market cap?

Caribou Biosciences’s market cap is $202.08M.

When is Caribou Biosciences’s upcoming earnings report date?

Caribou Biosciences’s upcoming earnings report date is Mar 16, 2026 which is in 116 days.

How were Caribou Biosciences’s earnings last quarter?

Caribou Biosciences released its earnings results on Nov 12, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.354 by $0.054.

Is Caribou Biosciences overvalued?

According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Caribou Biosciences pay dividends?

Caribou Biosciences does not currently pay dividends.

What is Caribou Biosciences’s EPS estimate?

Caribou Biosciences’s EPS estimate is -0.31.

How many shares outstanding does Caribou Biosciences have?

Caribou Biosciences has 93,123,240 shares outstanding.

What happened to Caribou Biosciences’s price movement after its last earnings report?

Caribou Biosciences reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.354. Following the earnings report the stock price went down -12.389%.

Which hedge fund is a major shareholder of Caribou Biosciences?

Currently, no hedge funds are holding shares in CRBU

Caribou Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-74.28%

Trailing 12-Months

Asset Growth

-40.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Caribou Biosciences

Caribou Biosciences, Inc. is a biotechnology company focused on harnessing the power of CRISPR gene editing technology to develop innovative therapies for various diseases. The company operates primarily in the life sciences sector, offering products and services that enable researchers and developers to utilize CRISPR for gene editing applications. Caribou's core products include its proprietary CRISPR platform, which allows for precise genetic modifications, and it partners with academic institutions and pharmaceutical companies to advance cellular therapies and other biotechnological applications.

Caribou Biosciences (CRBU) Earnings & Revenues

Historic Earnings Reports

CRBU Stock 12 Month Forecast

Average Price Target

$7.00

▲(274.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.42,3.003076923076923,3.586153846153846,4.169230769230769,4.752307692307692,5.335384615384616,5.918461538461538,6.501538461538461,7.084615384615384,7.667692307692308,8.25076923076923,8.833846153846153,9.416923076923077,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.42,2.772307692307692,3.1246153846153844,3.476923076923077,3.829230769230769,4.181538461538461,4.533846153846154,4.886153846153846,5.2384615384615385,5.590769230769231,5.943076923076923,6.295384615384616,6.647692307692308,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.42,2.310769230769231,2.2015384615384614,2.0923076923076924,1.983076923076923,1.873846153846154,1.7646153846153845,1.6553846153846155,1.546153846153846,1.436923076923077,1.3276923076923077,1.2184615384615385,1.1092307692307692,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.16,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >